tiprankstipranks
Molecular Templates announces FDA accepts IND for MT-8421 ETB program
The Fly

Molecular Templates announces FDA accepts IND for MT-8421 ETB program

Molecular Templates announced that it has received clearance by the United States Food and Drug Administration following review of its Investigational New Drug Application, or "IND," to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors. "MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity," said Eric Poma, CEO and Chief Scientific Officer of MTEM.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MTEM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles